AAV9-Follistatin

AAV9-Follistatin is a gene therapy approach that uses an adeno-associated virus (AAV9) vector to deliver the follistatin gene. Follistatin is a protein that inhibits myostatin, a negative regulator of muscle growth, potentially enhancing muscle mass and strength. This therapy is significant for longevity and health optimization as it may help counteract age-related muscle loss and improve overall physical function.

Intelligence Profile

Safety Profile

Currently, there is limited evidence regarding the safety profile of AAV9-Follistatin due to the absence of published studies or safety data retrieved from PubMed. The ongoing clinical trial (NCT07443826) aims to investigate this therapy's effects but is still in the recruiting phase (Phase 1/2). As such, comprehensive safety information, including known side effects, contraindications, drug interactions, and specific populations that should avoid this therapy, is not yet available.

The absence of detailed data means that any conclusions about the safety of AAV9-Follistatin are speculative at this point. Further research outcomes from the ongoing trial will be necessary to develop a more complete understanding of the safety profile.

Disclaimer: This is general information and should not be considered medical advice. Please consult healthcare professionals for personal medical concerns.

AAV9-Follistatin

Free account required